|
Ein sehr wichtiger Schritt für cytomx, der zweite pdc mit abbvie CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration July 9, 2019 at 8:00 AM EDT -Triggers $10 Million Milestone Payment to CytomX- SOUTH SAN FRANCISCO, Calif., July 09, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody\u2122 therapeutic technology platform, today announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates (“PDC”). The target selection triggers a $10 million payment to CytomX from AbbVie. This is the second of two research targets available to AbbVie under the agreement. The companies are also advancing a clinical-stage asset, CX-2029, under a global co-development and licensing agreement. “The initiation of this additional program with AbbVie and the associated milestone payment reflects the growing strength of clinical proof of concept CytomX has achieved in support of the Probody platform. It also further underscores the potential of our unique technology to make meaningful differences for cancer patients. We are excited to start this new program with our AbbVie colleagues,” said Sean McCarthy D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. |
|
| aus der Diskussion: | CytomX - ein bahnbrechender Ansatz in der Tumortherapie |
| Autor (Datum des Eintrages): | StefanR (09.07.19 15:48:27) |
| Beitrag: | 1,081 von 1,459 (ID:60986030) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |